SANCTIONS ORDERED AGAINST CHINESE MANUFACTURER OF CONTMINATED VALSARTAN - Honik LLC
16178
post-template-default,single,single-post,postid-16178,single-format-standard,bridge-core-3.0.1,qode-page-transition-enabled,ajax_fade,page_not_loaded,,side_area_uncovered_from_content,qode-child-theme-ver-1.0.0,qode-theme-ver-29.0,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.8.0,vc_responsive
 

SANCTIONS ORDERED AGAINST CHINESE MANUFACTURER OF CONTMINATED VALSARTAN

SANCTIONS ORDERED AGAINST CHINESE MANUFACTURER OF CONTMINATED VALSARTAN

Sanctions Ordered Against Chinese manufactured Of Contminated Valsartan

On May 10, 2024, a Special Master in the multi-district litigation about valsartan, losartan, and irbesartan drugs being contaminated with a carcinogen has ordered that the lead Chinese defendant, Zhejiang Huahai Pharmaceutical Co. Ltd., must pay sanctions for its refusal to produce documents or to have its CEO, Baohua Chen, appear for deposition. The order is attached here. Honik LLC’s Ruben Honik is co-lead plaintiffs’ counsel in the matter, and Honik LLC’s David Stanoch is plaintiffs’ liaison counsel to the plaintiff side.

Read More